bridge the effective use of pain-relieving medicine without abuse and safety concerns.
BU08028 prevents pain by accessing two sets of opioid receptors. Stimulation in both sets of receptors repressed pain, although one set of caused respiratory issues and continued motivation toward addiction and abuse.
The study concluded that there’s a need for future studies to use larger doses of BU08028 for longer periods of time during trials to confirm its safety for people and to explore other compounds that could produce optimal effects for pain management.
Author: Cesar Gamboa
Cesar Gamboa is a staff reporter and editor for Addiction Now covering topics ranging from legislation to scientific studies. He was previously a general assignment reporter for the Orange County Register. SoCal raised, lover of books, and avid mountain biker (when he wants to be). He can be reached at cesarg@addictionnow.com.
